

**Amendment to the Amendment in the Nature of a Substitute to H.R. 3  
Offered by Rep. Arrington of Texas**

The amendment would create a Chief Pharmaceutical Negotiator at the Office of the United States Trade Representative.



**AMENDMENT**

**OFFERED BY MR. ARRINGTON OF TEXAS**

Add at the end the following (and conform the table of contents accordingly):

1       **TITLE VI—MISCELLANEOUS**

2       **SEC. 601. CHIEF PHARMACEUTICAL NEGOTIATOR AT THE**  
3                       **OFFICE OF THE UNITED STATES TRADE REP-**  
4                       **RESENTATIVE.**

5       (a) IN GENERAL.—Section 141 of the Trade Act of  
6 1974 (19 U.S.C. 2171) is amended—

7               (1) in subsection (b)(2)—

8                       (A) by striking “and one Chief Innovation  
9                       and Intellectual Property Negotiator” and in-  
10                      serting “one Chief Innovation and Intellectual  
11                      Property Negotiator, and one Chief Pharma-  
12                      ceutical Negotiator”;

13                     (B) by striking “or the Chief Innovation  
14                     and Intellectual Property Negotiator” and in-  
15                     serting “the Chief Innovation and Intellectual  
16                     Property Negotiator, or the Chief Pharma-  
17                     ceutical Negotiator”; and

18                     (C) by striking “and the Chief Innovation  
19                     and Intellectual Property Negotiator” and in-

1           serting “the Chief Innovation and Intellectual  
2           Property Negotiator, and the Chief Pharma-  
3           ceutical Negotiator”; and

4           (2) in subsection (c), by adding at the end the  
5           following new paragraph:

6           “(7) The principal function of the Chief Phar-  
7           maceutical Negotiator shall be to conduct trade ne-  
8           gotiations and to enforce trade agreements relating  
9           to United States pharmaceutical products and serv-  
10          ices. The Chief Pharmaceutical Negotiator shall be  
11          a vigorous advocate on behalf of United States phar-  
12          maceutical interests. The Chief Pharmaceutical Ne-  
13          gotiator shall perform such other functions as the  
14          United States Trade Representative may direct.”.

15          (b) COMPENSATION.—Section 5314 of title 5, United  
16          States Code, is amended by striking “Chief Innovation  
17          and Intellectual Property Negotiator, Office of the United  
18          States Trade Representative.” and inserting the following:

19                 “Chief Innovation and Intellectual Property Ne-  
20                 gotiator, Office of the United States Trade Rep-  
21                 resentative.

22                 “Chief Pharmaceutical Negotiator, Office of the  
23                 United States Trade Representative.”.

24          (c) REPORT REQUIRED.—Not later than the date  
25          that is one year after the appointment of the first Chief

1 Pharmaceutical Negotiator pursuant to paragraph (2) of  
2 section 141(b) of the Trade Act of 1974, as amended by  
3 subsection (a), and annually thereafter, the United States  
4 Trade Representative shall submit to the Committee on  
5 Finance of the Senate and the Committee on Ways and  
6 Means of the House of Representatives a report describing  
7 in detail—

8           (1) enforcement actions taken by the United  
9       States Trade Representative during the one-year pe-  
10      riod preceding the submission of the report to en-  
11      sure the protection of United States pharmaceutical  
12      products and services; and

13           (2) other actions taken by the United States  
14      Trade Representative to advance United States  
15      pharmaceutical products and services.

